NCT02077946已完成不适用
A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,059
- 试验地点
- 1
- 主要终点
- Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction
研究概览
简要总结
This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients from EMR (electronic medical record) system in the primary care in Sweden
- •Patients equal to or more than 18 years of age
- •Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013
- •Minimum of 180 days of prior follow-up/history within the database before their index date
排除标准
- •Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes related)
- •Female patients with gestational diabetes during pregnancy
- •Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve
研究组 & 干预措施
Liraglutide / Sitagliptin
干预措施: liraglutide (Drug)
Liraglutide / Sitagliptin
干预措施: sitagliptin (Drug)
结局指标
主要结局
Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction
时间窗: Day 0, Day 180
次要结局
- Change in creatinine(Day 0, Day 180)
- Percent (%) of patients with HbA1c (glycosylated haemoglobin) reduction at least 1 %-point and weight reduction at least 3% (NICE clinical guidelines, liraglutide only)(Day 0, Day 180)
- Change in lipids (HDL, LDL and triglycerides, in mmol/L)(Day 0, Day 180)
- HbA1c (NGSP standard, in %) change(Day 0, Day 180)
- Change in weight (in kilograms)(Day 0, Day 180)
- Change in blood pressure (systolic, in mmHg)(From baseline to 180 days of therapy)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in EuropeDiabetesDiabetes Mellitus, Type 2NCT01890993Novo Nordisk A/S952
招募中
不适用
Electronic Archive of Patients With Diagnosis and Suspected Prenatal Diagnosis of Aortic CoarctationAortic CoarctationNCT06759103IRCCS Azienda Ospedaliero-Universitaria di Bologna150
已完成
不适用
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)Macular EdemaNCT01445626Allergan87
招募中
不适用
Post-Market Clinical Follow-up (PMCF) Study of the Pitch-Patch for the Augmentation or Reinforcement of the Rotator CuffRotator Cuff TearsRotator Cuff Tears of the ShoulderRotator Cuff InjuriesRotator Cuff TearNCT05906004Xiros Ltd37
已完成
不适用
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein OcclusionMacular OedemaRetinal Vein OcclusionNCT01566526Allergan26